Treatment & Outcomes of Diabetes Patients During the COVID-19 Pandemic

After nearly six months of coping with the COVID-19 pandemic, InCrowd wanted to understand how diabetes patients and providers are managing their diseases and maintaining their treatment paradigms amidst the various challenges that threaten patient safety and access to care.

We would like to thank our friends at Market Cube for their help in sourcing this important research.

Methodology:

• Method:
  • Physicians: 8-Minute MicroSurvey via InCrowd
  • Patients: 2-Minute MicroSurvey via InCrowd and Market Cube
• Crowds:
  • US Primary Care Physicians (PCPs) and Endocrinologists (Endos)
  • Diabetes Patients
• Sample Size:
  • Physicians: 102 Total
    • PCPs: 51%
    • Endos: 49%
  • Patients: 102 Total
• Fielding Period:
  • Physicians: August 4, 2020 (3 hours)
  • Patients: August 5-7, 2020 (48 hours)
• Screening Criteria
  • Physicians currently treating at least 15 diabetes type 1 patients and 25 type 2 patients
  • Patients actively seeking treatment for diabetes type 1 or type 2

InCrowd’s other COVID-19 Tracking Reports:

• COVID-19 Vaccine Development Report
• Physician Tracking Report – Wave 6
• Non-Frontline Specialist Tracking Report – Wave 2
• Patient Tracking Report—Wave 2
• Telemedicine & Remote-Patient Monitoring Report